

## **GARP Antibody (Center) Blocking Peptide**

Synthetic peptide Catalog # BP6647c

## **Specification**

## **GARP Antibody (Center) Blocking Peptide - Product Information**

Primary Accession

014392

# GARP Antibody (Center) Blocking Peptide - Additional Information

**Gene ID 2615** 

#### **Other Names**

Leucine-rich repeat-containing protein 32, Garpin, Glycoprotein A repetitions predominant, GARP, LRRC32, D11S833E, GARP

# **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a href=/products/AP6647c>AP6647c</a> was selected from the Center region of human GARP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **GARP Antibody (Center) Blocking Peptide - Protein Information**

Name LRRC32 {ECO:0000303|PubMed:19651619, ECO:0000312|HGNC:HGNC:4161}

## **Function**

Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:<a href="http://www.uniprot.org/citations/19750484" target="\_blank">19750484</a>, PubMed:<a href="http://www.uniprot.org/citations/19651619" target="\_blank">19651619</a>, PubMed:<a href="http://www.uniprot.org/citations/22278742" target="\_blank">22278742</a>). Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta (PubMed:<a href="http://www.uniprot.org/citations/22278742" target="\_blank">22278742</a>). Able to outcompete LTBP1 for binding to LAP regulatory chain of TGF-beta (PubMed:<a href="http://www.uniprot.org/citations/22278742" target="\_blank">22278742</a>). Controls activation of TGF-beta-1 (TGFB1) on the surface of activated regulatory T-cells (Tregs) (PubMed:<a



Tel: 858.875.1900 Fax: 858.875.1999

href="http://www.uniprot.org/citations/19750484" target="\_blank">19750484</a>, PubMed:<a href="http://www.uniprot.org/citations/19651619" target="\_blank">19651619</a>). Required for epithelial fusion during palate development by regulating activation of TGF-beta-3 (TGFB3) (By similarity).

### **Cellular Location**

Cell membrane; Single-pass type I membrane protein. Cell surface

### **Tissue Location**

Preferentially expressed in regulatory T-cells (Tregs).

# **GARP Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

## • Blocking Peptides

**GARP Antibody (Center) Blocking Peptide - Images** 

GARP Antibody (Center) Blocking Peptide - Background

GARP is a type I membrane protein which contains 20 leucine-rich repeats.

# **GARP Antibody (Center) Blocking Peptide - References**

Wang, R., PLoS ONE 3 (7), E2705 (2008) Maire, G., Genes Chromosomes Cancer 37 (4), 389-395 (2003)